Challenges in developing personalized neoantigen cancer vaccines

PD Katsikis, KJ Ishii, C Schliehe - Nature Reviews Immunology, 2024 - nature.com
The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …

Nanoparticle-based adjuvants and delivery systems for modern vaccines

B Filipić, I Pantelić, I Nikolić, D Majhen… - Vaccines, 2023 - mdpi.com
Ever since the development of the first vaccine, vaccination has had the great impact on
global health, leading to the decrease in the burden of numerous infectious diseases …

Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines

S Gupta, S Pellett - Toxins, 2023 - mdpi.com
Vaccines are one of the most effective strategies to prevent pathogen-induced illness in
humans. The earliest vaccines were based on live inoculations with low doses of live or …

Periodic mesoporous organosilica as a nanoadjuvant for subunit vaccines elicits potent antigen-specific germinal center responses by activating naive B cells

F Li, X Feng, J Huang, M Zhang, W Liu, X Wang… - ACS …, 2023 - ACS Publications
Infection diseases such as AIDS and COVID-19 remain challenging in regard to protective
vaccine design, while adjuvants are critical for subunit vaccines to induce strong, broad, and …

From periphery to center stage: 50 years of advancements in innate immunity

S Carpenter, LAJ O'Neill - Cell, 2024 - cell.com
Over the past 50 years in the field of immunology, something of a Copernican revolution has
happened. For a long time, immunologists were mainly concerned with what is termed …

Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia

E Kawahara, T Shibata, T Hirai, Y Yoshioka - Frontiers in Immunology, 2023 - frontiersin.org
Introduction Respiratory syncytial virus (RSV) vaccines targeting the fusion glycoprotein (F
protein) are highly effective clinically in preventing RSV challenges. The attachment …

Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate

G Desalegn, CS Tamilselvi, JM Lemme-Dumit… - npj Vaccines, 2024 - nature.com
Diarrhea caused by Shigella has been associated with high morbidity and mortality in young
children worldwide. There are no licensed vaccines, and those clinically advanced have …

Understanding immunity to influenza: implications for future vaccine development

RA Tripp - Expert Review of Vaccines, 2023 - Taylor & Francis
Introduction Influenza virus changes its genotype through antigenic drift or shift making it
difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) …

Vaccine Strategies to Elicit Mucosal Immunity

Y Song, F Mehl, SL Zeichner - Vaccines, 2024 - mdpi.com
Vaccines are essential tools to prevent infection and control transmission of infectious
diseases that threaten public health. Most infectious agents enter their hosts across mucosal …

Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach

Y Xing, JR Clark, JD Chang, JJ Zulk… - Infection and …, 2024 - Am Soc Microbiol
ABSTRACT Extraintestinal pathogenic Escherichia coli (ExPEC) is a leading cause of
worldwide morbidity and mortality, the top cause of antimicrobial-resistant (AMR) infections …